

Skin Cancer Surgery Priority Setting Partnership (PSP)

Steering Group (SG) Meeting 1

2:30pm-4:30pm Monday 7th September 2020

Virtual

MEETING NOTES & ACTIONS

Meeting Purpose	<ul style="list-style-type: none"> • Introduce SG members • Introduce the JLA Priority Setting Partnership process • Discuss the scope for this PSP • Discuss PSP Administration 	
Meeting Action Points		
<p>Introduction to the JLA PSP Process</p> <p>Suzannah shared a presentation introducing the James Lind Alliance and the process of a PSP. The JLA has completed 100 PSPs all over the world. The key principles are transparency, inclusion/exclusion, equality of voice and using existing evidence base. The process involves primary survey to gather uncertainties, analysis, secondary survey and agreement of “Top 10” research priorities to be disseminated to funders and researchers. The process should take 12-18 months.</p>		
Action	Who	When
1. Copy of JLA introduction presentation to be sent to SG Members	Suzannah Kinsella	Before SG Meeting 2: Friday 11 th September 2020 (Completed)
PSP Scope		
<p>David Veitch introduced how concept of the skin cancer surgery PSP was formulated. It was generated as part of UK DCTN call for themed research 2019. It is now co-funded by the UK DCTN and BSDS.</p> <p>A draft scope was shared with SG Members by Aaron Wernham and discussed.</p> <p>During discussions around inclusion criteria, it was clarified that skin cancer predominately comprised of BCC, SCC, melanoma and less frequently Merkle cell carcinoma. The SG acknowledged that other rarer forms of skin cancer exist, but as they arise at a lower frequency, they are unlikely to make “The Top Ten”. It was decided that we should not exclude at this stage.</p> <p>SG also clarified that all surgical procedures should be included: biopsy, incision, excision, cautery and curettage, shave, Mohs micrographic surgery.</p>		

During discussions regarding exclusion criteria, Eric Deeson had concerns regarding excluding monitoring for recurrence as felt this was a very important part of treatment for skin cancer. A few clinicians recognised the important of this part of the skin cancer pathway but felt that it was important to focus on the surgical aspect during this PSP. The SG acknowledge that this is first and currently only PSP in skin cancer and hence the temptation to keep the scope broad to cover as much as possible. Maggie McPhee confirmed there were currently no other skin cancer PSPs in the pipeline, but promoted focusing questions. Rachel Abbott recommended excluding from the analysis of this PSP but still gathering data on this as it was felt to be an important clinical question.

Amended draft inclusion and exclusion criteria were circulated after the meeting as below:

Draft Inclusion Criteria:

- Uncertainties relevant to skin cancer surgery for all types of primary skin cancer.
- Examples include anything related to the consent, anaesthesia, antibiotics, variations in the procedure, scar outcomes, wound care, follow up related to scar outcome or surgical outcome.

Draft Exclusion Criteria:

- All other types of surgery not relevant to skin cancer surgery.
- Questions relevant to removal of benign lesions only or cosmetic skin procedures.
- Questions solely related to other treatment modalities for skin cancer e.g. Radiotherapy or Laser unless as a comparison to surgery.
- Surgery only relevant to precancerous changes such as Actinic Keratosis or Bowens disease (but ? Include lentigo maligna or melanoma in situ i.e. precancer to melanoma).
- Surgery for regional skin cancer recurrence or metastatic disease
- Questions related to prevention of skin cancer, monitoring for recurrence, service delivery and service management.
- Questions related specifically to skin cancer in the paediatric population <18 years old.

To further discuss on Friday 11/9/20:

- What about precancerous changes
- Surgery for all types of cancer
- Surgery for regional or metastatic disease
- Questions related to surgery versus other modalities or a type of cancer
- Follow up for skin cancer monitoring beyond follow up for wound or scar check
- Age restrictions- adult only or to include children

Action	Who	When
2. Members to provide feedback on updated	SG members	Email by Wednesday 9 th September 2020

Inclusion/ Exclusion criteria		
3. SG members to provide feedback on discussion points above	SG Members	Email by Wednesday 9 th September 2020
PSP Administration		
Items to be discussed on Friday 11/9/20:		
<ul style="list-style-type: none"> • What partner organisations will be helpful in promoting this PSP? • What days of the week/times of day are best for you to meet for monthly PSP meetings (allow 90mins). • Comments on the Terms of Reference document. • Discussion of the PSP timeline. • Review of the PSP steering group. 		
Action	Who	When
4. Members to consider PSP Administration	SG Members unable to attend meeting 11/9/20 to provide feedback	Email by Wednesday 9 th September 2020

Apologies received – J Rodrigues, C Wingfield, D Snow, D Thompson, D Grindlay

Attendees	Attended Y/N
John Holmes	Y
Eric Deeson	Y
Stuart Belshaw	N
Ayath Ullah	Y
Patricia Fairbrother	Y
Nigel Dunford	Y
Dr Aaron Wernham	Y
Dr David Veitch	Y
Dr Rachel Abbott	Y
Dr Jonathan Batchelor	Y
Dr Claudia Degiovanni	Y
Mr Jonathan Pollock	Y
Mr Jeremy Rodrigues	N
Ms Carrie Newlands	Y
Carrie Wingfield	N
Dr Sarah Worboys	N
Mr David Snow	N
Diane Thompson	N

Dr Stela Ziaj	y
Dr Alistair Brown	y
Dr Eleanor Earp	y
Maggie Mcphee	y
Douglas Grindlay	N
Suzannah Kinsella	y
Jackie Kervick	y

*T/c = joining via video/teleconference